PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA, 15-OHEPA, AND/OR 15-HETRE AND METHODS OF REDUCING SEBUM PRODUCTION USING SAME
The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used singly or in combination with anti-bacterial agents for the inhibition of sebum production.
1 . A method for reducing sebum production in a subject in need thereof, the method comprising: administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of DGLA, 15-OHEPA, or 15-HETrE.
2 . The method of claim 1 , wherein the pharmaceutical composition comprises about 0.1% to about 20 wt. % of DGLA, 15-HETrE and/or 15-OHEPA.
3 . The method of claim 2 , wherein the pharmaceutical composition comprises about 1.65 wt. % steareth-2, about 1.35 wt. % steareth-21, about 0.5 wt. % cetyl alcohol, about 0.2 wt. % ascorbyl palmitate, about 0.15 wt. % a-tocopherol, about 2.0 wt. % medium-chain triglycerides (e.g., Crodamol GTCC), about 2.0 wt. % myristyl myristate, about 4.0 wt. % isopropyl palmitate, about 1.0 wt. % glycerin, about 1.0 wt. % phenoxyethanol, about 0.1 wt. % ascorbic acid, about 0.8 wt. % carbomer, about 0.4 wt. % xanthan gum, about 0.5 wt. % liquid soy lecithin, and about 0.05 wt. % Mild Care 345 fragrance.
4 . The method of claim 2 , wherein the pharmaceutical composition comprising DGLA, 15-OHEPA, or 15-HETrE further includes a therapeutically effective amount of a retinoid analogue.
5 . The method of claim 4 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 1 wt. % of the retinoid analogue.
6 . The method of claim 1 , wherein the step of administering comprises topically applying the composition to an area of the skin.
7 . The method of claim 6 , wherein applying the composition results in about a 10%, 20%, 30%, 40%, 50% 60%, 70%, 80%, 90% or more reduction in an amount of sebum produced by the area of the skin.
8 . The method of claim 6 , wherein the step of administering comprises topically applying the composition to an area of the skin afflicted with acne lesions.
9 . The method of claim 8 , wherein the area of the skin afflicted with acne lesions is first washed prior to application of the pharmaceutical composition.
10 . The method of claim 8 , wherein the acne lesions are inflammatory type and/or non-inflammatory type lesions.
11 . The method of claim 10 , wherein the composition reduces about 10%, 20%, 30%, 40%, 50% 50%, 70%, 80%, 90% or more of the acne lesions.
12 . The method of claim 1 , wherein the acne is associated with Propionibacterium acnes.
13 . The method of claim 1 , wherein the pharmaceutical composition is administered to the subject once a day, twice a day, or three times a day.
14 . The method of claim 1 , wherein the pharmaceutical composition is a cream.
15 . The method of claim 1 , wherein the subject previously exhibited acne lesions.
16 . The method of claim 4 , wherein the retinoid analogue is adapalene.
17 . The method of claim 16 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 0.3 wt. % of adapalene.
18 . A product for use in the reduction of sebum production, the product comprising:
(i) a container; and
(ii) a pharmaceutical composition comprising a therapeutically effective amount of DGLA, 15-OHEPA, or 15-HETrE, releasably confined inside the container.
19 . The product of claim 18 , wherein the pharmaceutical composition comprises about 0.1% to about 20 wt. % of DGLA, 15-OHEPA, or 15-HETrE.
20 . The product of claim 19 , wherein the pharmaceutical composition comprises about 1.65 wt. % steareth-2, about 1.35 wt. % steareth-21, about 0.5 wt. % cetyl alcohol, about 0.2 wt. % ascorbyl palmitate, about 0.15 wt. % a-tocopherol, about 2.0 wt. % medium-chain triglycerides (e.g., Crodamol GTCC), about 2.0 wt. % myristyl myristate, about 4.0 wt. % isopropyl palmitate, about 1.0 wt. % glycerin, about 1.0 wt. % phenoxyethanol, about 0.1 wt. % ascorbic acid, about 0.8 wt. % carbomer, about 0.4 wt. % xanthan gum, about 0.5 wt. % liquid soy lecithin, and about 0.05 wt. % Mild Care 345 fragrance.
21 . The product of claim 18 , wherein the pharmaceutical composition comprising DGLA further includes a therapeutically effective amount of a retinoid analogue.
22 . The product of claim 21 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 1 wt. % of the retinoid analogue.
23 . The product of claim 22 , wherein the retinoid analogue is adapalene.
24 . The product of claim 23 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 0.3 wt. % of adapalene.
25 . The product of claim 18 , wherein the pharmaceutical composition comprising 15-OHEPA further includes a therapeutically effective amount of a retinoid analogue.
26 . The product of claim 25 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 1 wt. % of the retinoid analogue.
27 . The product of claim 26 , wherein the retinoid analogue is adapalene.
28 . The product of claim 27 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 0.3 wt. % of adapalene.
29 . The product of claim 18 , wherein the pharmaceutical composition comprising 15-HETrE further includes a therapeutically effective amount of a retinoid analogue.
30 . The product of claim 29 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 1 wt. % of the retinoid analogue.
31 . The product of claim 30 , wherein the retinoid analogue is adapalene.
32 . The product of claim 31 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 0.3 wt. % of adapalene.
33 . A method for reducing the efficacious dose of an agent used in the reduction of sebum, the method comprising: adding a therapeutically effective amount of DGLA, 15-OHEPA, or 15-HETrE to the agent.
34 . The method of claim 33 , wherein about 0.1% to about 20 wt. % of DGLA, 15-OHEPA, or 15-HETrE is added to the agent.
35 . The method of claim 33 , wherein the agent is isotretinoin.